Atlas Trials

PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma

Clinical trial NCT03226249 · UNKNOWN

Trial details

NCT number
NCT03226249
Sponsor
Northwestern University
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Classical Hodgkin LymphomaLymphocyte-Depleted Classical Hodgkin LymphomaLymphocyte-Rich Classical Hodgkin LymphomaMixed Cellularity Classical Hodgkin LymphomaNodular Sclerosis Classical Hodgkin Lymphoma
Start date
2017-11-09
Primary completion
2019-05-17
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.